The Medicines Company (NASDAQ:MDCO) – Analysts at Oppenheimer Holdings upped their FY2017 EPS estimates for shares of The Medicines in a report released on Thursday. Oppenheimer Holdings analyst J. Olson now expects that the company will earn ($8.93) per share for the year, up from their previous estimate of ($9.82). Oppenheimer Holdings currently has a “Hold” rating and a $50.00 target price on the stock. Oppenheimer Holdings also issued estimates for The Medicines’ Q4 2017 earnings at ($1.55) EPS, FY2019 earnings at ($1.43) EPS, FY2020 earnings at ($0.86) EPS and FY2021 earnings at $0.70 EPS.

MDCO has been the topic of a number of other reports. Citigroup Inc. reduced their target price on shares of The Medicines from $59.00 to $43.00 and set a “neutral” rating on the stock in a research report on Monday, July 17th. Zacks Investment Research raised shares of The Medicines from a “hold” rating to a “buy” rating and set a $41.00 target price on the stock in a research report on Tuesday, August 8th. Chardan Capital reaffirmed a “buy” rating and set a $85.00 target price on shares of The Medicines in a research report on Wednesday, September 20th. Guggenheim began coverage on shares of The Medicines in a research report on Monday, October 23rd. They set a “buy” rating and a $45.00 target price on the stock. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $54.00 target price on shares of The Medicines in a research report on Thursday, October 26th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $53.18.

COPYRIGHT VIOLATION WARNING: “Oppenheimer Holdings Brokers Raise Earnings Estimates for The Medicines Company (MDCO)” was originally reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.dailypolitical.com/2017/10/31/oppenheimer-holdings-brokers-raise-earnings-estimates-for-the-medicines-company-mdco.html.

The Medicines (NASDAQ:MDCO) opened at 28.46 on Monday. The Medicines has a 12-month low of $28.00 and a 12-month high of $55.95. The stock’s market cap is $2.05 billion. The stock has a 50 day moving average price of $34.85 and a 200 day moving average price of $39.06.

The Medicines (NASDAQ:MDCO) last released its quarterly earnings data on Wednesday, October 25th. The company reported ($0.42) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.37) by $0.95. The firm had revenue of $16.87 million for the quarter, compared to the consensus estimate of $26.06 million. The Medicines had a negative return on equity of 149.81% and a negative net margin of 767.94%. The company’s quarterly revenue was down 55.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.64) earnings per share.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. boosted its stake in shares of The Medicines by 341.2% during the first quarter. PNC Financial Services Group Inc. now owns 2,109 shares of the company’s stock valued at $104,000 after purchasing an additional 1,631 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of The Medicines by 10.6% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,753 shares of the company’s stock valued at $105,000 after purchasing an additional 264 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of The Medicines by 5.1% during the first quarter. Envestnet Asset Management Inc. now owns 2,496 shares of the company’s stock valued at $122,000 after purchasing an additional 120 shares in the last quarter. First Mercantile Trust Co. boosted its stake in shares of The Medicines by 2.5% during the second quarter. First Mercantile Trust Co. now owns 4,767 shares of the company’s stock valued at $181,000 after purchasing an additional 114 shares in the last quarter. Finally, Bluefin Trading LLC bought a new position in shares of The Medicines during the second quarter valued at approximately $214,000.

About The Medicines

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Earnings History and Estimates for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with MarketBeat.com's FREE daily email newsletter.